Ware Lab

Publications

Latham, TS; Babich, SM; Yego-Kosgei, F; Czabanowska, K; Ware, RE. Building capacity for sickle cell stroke prevention in low-resource settings. Discover Public Health. 2025; 22(1):881.

Girgis, MK; Lopachin, TR; Hallett, TC; Briones, MA; Desai, NJ; Mcelhinney, KE; Ware, RE; Yee, MEM. Prolonged, Unintentional Overdose of Hydroxyurea in a Child With Sickle Cell Anemia. Pediatric Blood and Cancer. 2025; e70076.

Tomlinson, GA; Backeljauw, P; Mochamah, G; Smart, LR; Latham, TS; Ware, RE; Williams, TN. Development of disease-specific growth curves from Kenyan children with sickle cell anemia. Blood Global Hematology. 2025; 1(3):100031.

Niss, O; Ware, RE; Quinn, CT. A New First-Line Option for Pediatric ITP-Incremental Progress or Paradigm Shift? Journal of the American Medical Association (JAMA). 2025; 334(20):1802-1803.

Shukla, RP; Aroosh, M; Cazelles, R; Ware, RE; Vinks, AA; Ben-Yoav, H. Microsensor Array for the Electrochemical Analysis of Hydroxyurea in Blood Samples of Children Affected by Sickle Cell Anemia. Analytical Chemistry. 2025; 97(44):24399-24414.

Latham, T; Kiyaga, C; Hernandez, A; Nakafeero, M; Kadde, N; Khainza, P; Stuber, S; Ndeezi, G; Aceng, J; Ware, R. Health status of Ugandan children born with sickle cell anemia and congenital HIV identified through newborn screening. Blood. 2025; 146(Supplement 1):2668.

Nnodu, O; Awuonda, B; Chirande, L; Kiyaga, C; Segbefia, C; Chunda-Liyoka, C; Franklin, P; Zapfel, A; Benoit, M; Thompson, A; Coetzer, T; Ware, R; Novelli, E; Green, NS. The ASH consa consortium on newborn screening in Africa for sickle cell disease: Interim updates of progress in screening, follow-up and supporting initiatives. Blood. 2025; 146(Supplement 1):944-944.

Smart, L; Dei-Adomakoh, Y; Lane, A; Ekpale, P; Koni, L; Corquaye, O; Mensah, E; Stuber, S; Latham, T; Segbefia, C; Ware, R. Benefits of hydroxyurea in hemoglobin SC: Results of the open-label phase of the prospective identification of variables as outcomes for treatment (PIVOT) trial. Blood. 2025; 146(Supplement 1):409.

Elgammal, Y; Hamdan, L; Risinger, M; Kostantinidis, D; Seu, K; Mcelhinney, K; Niss, O; Nemeth, E; Quinn, C; Ware, R; Kalfa, T. Biomarkers of ineffective erythropoiesis in patients with sickle cell anemia, at baseline and while treated with hydroxyurea, in comparison to patients with other iron-loading red cell disorders. Blood. 2025; 146(Supplement 1):4686.

Tshilolo, L; Tomlinson, G; Smart, L; Latham, T; Olupot-Olupot, P; Santos, B; Aygun, B; Stuber, S; Lane, A; Williams, T; Ware, R. Splenomegaly patterns and clinical impact in African children with sickle cell anemia on hydroxyurea treatment. Blood. 2025; 146(Supplement 1):2971-2971.

Smart, L; Ambrose, E; Charles, M; Mcelhinney, K; Lane, A; Stuber, S; Latham, T; Ware, R. Pharmacokinetic (PK)-guided vs weight-based dosing of hydroxyurea for tanzanian children with sickle cell anemia. Blood. 2025; 146(Supplement 1):2959-2959.

Setayesh, T; Tijani, A; Kaur, H; Khanal, S; Zhu, Z; Chi, M; Kincaid, A; Ware, R; Malik, P. Oxidative stress and hemoglobin-c denaturation drive hemoglobin SC pathophysiology and can be ameliorated by antioxidants and hydroxyurea. Blood. 2025; 146(Supplement 1):7.

Ware, R; Opoka, R; Latham, T; Kasirye, P; Kasembo, P; Hume, HA; Birungi, I; Kadde, N; Wambaka, B; Nakafeero, M; Lane, A; John, C. Safety and efficacy of ten years of hydroxyurea treatment for young children with sickle cell anemia in Uganda. Blood. 2025; 146(Supplement 1):412.

Power-Hays, A; Kincaid, A; Mcelhinney, K; Latham, T; Quinn, C; Frenck, R; Ware, R. Measles vaccine-induced sero-protection among children with sickle cell anemia. Blood. 2025; 146(Supplement 1):1168.

Rios, CR; Lu, M; Hanson, K; Savidge, E; Ward, T; Korpik, J; Reynaud, M; Ware, R; Kalfa, T; Quinn, C. Imaging flow cytometry for detection of red blood cell inclusions: A quantitative approach to assess splenic filtration function in sickle cell disease. Blood. 2025; 146(Supplement 1):1188.

Quinn, C; Kincaid, A; Mcelhinney, K; Korpik, J; Kalfa, T; Ware, R. Feasibility, reliability, and accuracy of point-of-care measurements of fetal hemoglobin. Blood. 2025; 146(Supplement 1):4739-4739.

Power-Hays, A; Namazzi, R; Mcelhinney, K; Kincaid, A; Kato, C; Aliwuya, S; Opoka, R; Conroy, A; John, C; Hume, HA; Stuber, S; Latham, T; Ware, R. Full assessment of clinical transfusion support (FACTS): A prospective Study to determine the burden of sickle cell anemia on pediatric blood transfusion use in a malaria-endemic region in Africa. Blood. 2025; 146(Supplement 1):300-300.

Costa, E; Ware, R; Tshilolo, L; Luzzatto, L. Thirty Years of Hydroxyurea for Sickle Cell Anemia - Scientific Progress, Global Health Gaps. New England Journal of Medicine. 2025; 393(16):1556-1559.

Muteti, M; Akoko, E; Nyakundi, C; Mochamah, G; Makale, J; Ombati, P; Tawa, B; Nyanjom, S; Boateng, LA; Ware, RE; Williams, TN; Uyoga, S. Erythrocyte alloimmunization in children with sickle cell anemia living in Kilifi, Kenya. Blood Global Hematology. 2025; 1(2):100016.

Namazzi, R; Mellencamp, KA; Opoka, RO; Datta, D; Lima-Cooper, G; Liepmann, C; Sherman, J; Rodriguez, A; Kazinga, C; Ware, RE; Abreu, M; Schwantes-An, T-H; John, CC; Conroy, AL. Circulating Immune Complexes and Glucose-6-Phosphate Dehydrogenase Deficiency Predict Recurrent Blackwater Fever in Ugandan Children With Severe Malaria. Journal of Infectious Diseases. 2025; 232(2):285-297.

Williams, TN; Ware, RE. Malaria prophylaxis in sickle cell anaemia: some answers, more questions. The Lancet Infectious Diseases. 2025; 25(6):601-602.

Ambrose, EE; Sabuni, PA; Jason Iii, DP; Ware, RE; Makubi, AN; Smart, LR. Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis. Blood Global Hematology. 2025; 1(1).

Power-Hays, A; Namazzi, R; Dong, M; Kazinga, C; Kato, C; Aliwuya, S; Mcelhinney, K; Conroy, AL; Lane, A; John, C; Vinks, AA; Latham, T; Opoka, RO; Ware, RE. The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. British Journal of Clinical Pharmacology. 2025; 91(6):1865-1872.

Quinn, CT; Ware, RE. The modern use of hydroxyurea for children with sickle cell anemia. Haematologica. 2025; 110(5):1061-1073.

Machogu, E; Aanyu-Tukamuhebwa, H; Mellencamp, K; Birungi, I; Namutangula, B; Namazzi, R; Latham, T; Opoka, R; Ware, R; Davis, SD; John, C. Benefits of Hydroxyurea in Mitigating Early Onset Lung Disease in Children With Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine. 2025; 211(Abstracts):a1272-a1272.

Nieves, RM; Latham, T; Marte, N; Berges, M; Sánchez, LM; Urcuyo, G; Florencio, C; Gonzalez, C; Del Villar, P; Chen, S; Schultz, WH; Lane, AC; Mena, R; Ware, RE. Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial. Blood advances. 2025; 9(8):1791-1800.

Power-Hays, A; Namazzi, R; Dong, M; Kazinga, C; Kato, C; Aliwuya, S; Mcelhinney, K; Conroy, AL; Lane, A; John, C; Vinks, AA; Latham, T; Opoka, RO; Ware, RE. The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. British Journal of Clinical Pharmacology. 2025; 91(6):1865-1872.

Quinn, CT; Ware, RE. The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease? Pediatric Blood and Cancer. 2025; 72(3):e31475.

Dei-Adomakoh, YA; Segbefia, CI; Latham, TS; Lane, AC; Dzefi-Tettey, K; Amissah-Arthur, K; Corquaye, O; Korang, L; Mensah, E; Ekpale, P; Seedah, D; Stuber, SE; Smart, LR; Ware, RE. Hydroxyurea for Children and Adults with Hemoglobin SC Disease. NEJM Evid. 2025; 4(2):EVIDoa2400402.

Power-Hays, A; Namazzi, R; Kato, C; Mcelhinney, KE; Conroy, AL; Hume, H; John, C; O'hara, SM; Stuber, SE; Lane, A; Latham, TS; Opoka, RO; Ware, RE. Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial. Acta Haematologica. 2025; 148(2):208-219.

Costa, E; Ware, RE; Tshilolo, L; Makani, J; Leufkens, HGM; Luzzatto, L. Globalization in clinical drug development for sickle cell disease. American Journal of Hematology. 2025; 100(1):4-9.

Latham, TS; Czabanowska, K; Babich, S; Yego-Kosgei, F; Shook, LM; Ware, RE. Primary Stroke Screening and Hydroxyurea Treatment for Sickle Cell Anemia in Pediatric Healthcare Settings in East and Central Africa: A Narrative Review of Capacity Gaps and Opportunities. Public Health Reviews. 2025; 46:1608359.

Latham, TS; Ware, RE; Shook, LM. Assessing educational needs of sickle cell anemia healthcare providers in sub-Saharan Africa and the Caribbean. Frontiers in Public Health. 2025; 13:1693285.

Segbefia, CI; Smart, LR; Stuber, SE; Amissah-Arthur, KN; Dzefi-Tettey, K; Ekpale, P; Mensah, E; Lane, AC; Ghunney, W; Tagoe, LG; Oteng, A; Amoako, E; Latham, TS; Dei-Adomakoh, YA; Ware, RE. Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub-Saharan Africa. British Journal of Haematology. 2024; 205(6):2470-2480.

Latham, TS; Czabanowska, K; Babich, S; Yego, F; Ware, RE. Stroke Training, Research, and Education Toward Capacity with Hydroxyurea (STRETCH) Blood. 2024; 144(Supplement 1):2242-2242.

Uyoga, S; Muteti, M; Makale, J; Mochamah, G; Ware, RE; Williams, TN. RED Blood Cell Alloimmunization in Sickle Cell Anaemia Patients in Kilifi, Kenya. Blood. 2024; 144(Supplement 1):5602-5602.

Smart, LR; Ambrose, EE; Charles, M; Mcelhinney, K; Latham, TS; Stuber, SE; Ware, RE. Pharmacokinetic (PK)-Guided Dosing of Hydroxyurea for Tanzanian Children with Sickle Cell Anemia. Blood. 2024; 144(Supplement 1):289-289.

Awuonda, BO; Kiyaga, C; Chirande, L; Franklin, PC; Nnodu, OE; Ambrose, EE; Dogara, LG; Chunda-Liyoka, CM; Segbefia, CI; Coetzer, TL; Ware, RE. Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa: Initial Results of the ASH Consortium on Newborn Screening in Africa (CONSA) Program. Blood. 2024; 144(Supplement 1):541-541.

Prus, K; Evans, A; Matatiyo, A; Mapurisa, G; Nonganonga, M; Mutafya, T; Banda, K; Misiri, M; Kamija, M; Mzikamanda, RR; Westmoreland, KD; Ware, RE. Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching. Blood. 2024; 144(Supplement 1):4032.

Power-Hays, A; Mcelhinney, KE; Latham, TS; Williams, TN; Mochamah, G; Olupot-Olupot, P; Paasi, G; Reid, ME; Rankine-Mullings, A; Opoka, R; John, CC; Mcgann, PT; Quinn, CT; Stuber, SE; Ware, RE. Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts. Blood. 2024; 144(Supplement 1):542-542.

Williams, TN; Mochamah, G; Uyoga, S; Nyutu, G; Latham, TS; Backeljauw, P; Ware, RE; Tomlinson, GA. Growth Curves for Children Living with Sickle Cell Anemia in Kilifi County, Kenya, Do Not Follow Who Curves for Normal Children. Blood. 2024; 144(Supplement 1):5315-5315.

Ambrose, EE; Tomlinson, GA; Ngoya, PS; Stuber, SE; Latham, TS; Makubi, AN; Ware, RE; Smart, LR. Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial. Blood. 2024; 144(Supplement 1):2495-2495.

Kiyaga, C; Ambrose, EE; Awuonda, BO; Chirande, L; Chunda-Liyoka, CM; Dogara, LG; Franklin, PC; Nnodu, OE; Segbefia, CI; Ware, RE; Coetzer, TL. Building Capacity in Sub-Saharan Africa to Address Sickle Cell Disease: The Consortium on Newborn Screening in Africa (CONSA) Blood. 2024; 144(Supplement 1):520-520.

Power-Hays, A; Dong, M; Punt, N; Mizuno, T; Smart, LR; Vinks, AA; Ware, RE. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia. Clinical Pharmacology and Therapeutics. 2024; 116(3):670-677.

Sadaf, A; Dong, M; Pfeiffer, A; Korpik, J; Kalfa, TA; Latham, T; Vinks, AA; Ware, RE; Quinn, CT. A pharmacokinetic-pharmacodynamic analysis of l-glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy. British Journal of Haematology. 2024; 205(3):1147-1158.

Aygun, B; Lane, A; Smart, LR; Santos, B; Tshilolo, L; Williams, TN; Olupot-Olupot, P; Stuber, SE; Tomlinson, G; Latham, T; Ware, RE. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial. The Lancet Haematology. 2024; 11(6):e425-e435.

Costa, E; Isgrò, A; De Montalembert, M; Leufkens, HGM; Ware, RE; De Franceschi, L. Successes and pitfalls in orphan drug development for sickle cell disease. Blood advances. 2024; 8(10):2455-2465.

Namazzi, R; Bond, C; Conroy, AL; Datta, D; Tagoola, A; Goings, MJ; Jang, JH; Ware, RE; Opoka, R; John, CC. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood. 2024; 143(14):1425-1428.

Power-Hays, A; Tomlinson, GA; Tshilolo, L; Santos, B; Williams, TN; Olupot-Olupot, P; Smart, LR; Aygun, B; Lane, A; Stuber, SE; Latham, T; Ware, RE. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. American Journal of Hematology. 2024; 99(4):625-632.

Siegert, TF; Opoka, RO; Nakafeero, M; Carman, A; Mellencamp, KA; Latham, T; Hume, H; Lane, A; Ware, RE; Ssenkusu, JM; John, CC; Conroy, AL. Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy. Blood Vessels, Thrombosis & Hemostasis. 2024; 1(1):100001.

Sadaf, A; Dong, M; Pfeiffer, A; Latham, T; Kalfa, T; Vinks, AA; Ware, RE; Quinn, CT. A Population Pharmacokinetic Analysis of L-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects. Clinical Pharmacokinetics. 2024; 63(3):357-365.

Ware, RE; Quinn, CT. The bold promise of gene therapy for sickle cell disease. British Journal of Haematology. 2024; 204(2):381-382.

Shook, LM; Ware, RE. Screening for haemoglobin disorders: One size may not fit all. British Journal of Haematology. 2024; 204(1):26-28.

Teigen, D; Opoka, RO; Kasirye, P; Nabaggala, C; Hume, HA; Blomberg, B; John, CC; Ware, RE; Robberstad, B. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. PharmacoEconomics (Auckland). 2023; 41(12):1603-1615.

Mcelhinney, K; Smart, LR; Howard, TA; Power-Hays, A; Ware, RE. A Novel, Rapid, and Accurate Quantitative Hydroxyurea Assay. Blood. 2023; 142(Supplement 1):2530.

Sadaf, A; Dong, M; Korpik, J; Pfeiffer, A; Kalfa, TA; Latham, TS; Vinks, AA; Ware, RE; Quinn, CT. Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis. Blood. 2023; 142(Supplement 1):1145.

Rankine-Mullings, AE; Soares, D; Aldred, K; Chang-Lopez, S; Wisdom-Phipps, ME; Schultz, W; Latham, TS; Stuber, SE; Jackson, P; Ware, RE; Reid, ME. Hydroxyurea Improves Intelligence Quotient Scores in Children with Sickle Cell Anemia and Elevated Transcranial Doppler Velocity. Blood. 2023; 142(Supplement 1):797.

Teoh, Z; Simpson, BN; Howard, T; Mcelhinney, K; Ware, R; Mena, R; Schlaudecker, EP. Codetection of Plasmodium falciparum in Children Hospitalized With Dengue Fever in the Dominican Republic. Pediatric Infectious Disease Journal. 2023; 42(11):965-968.

Safeukui, I; Ware, RE; Mohandas, N; Haldar, K. Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood advances. 2023; 7(19):5970-5981.

Smart, LR; Segbefia, CI; Latham, TS; Stuber, SE; Amissah-Arthur, KN; Dzefi-Tettey, K; Lane, AC; Dei-Adomakoh, YA; Ware, RE. Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. Trials. 2023; 24(1):603.

Rankine-Mullings, A; Keenan, R; Chakravorty, S; Inusa, B; Telfer, P; Velangi, M; Ware, RE; Moss, JJ; Lloyd, AL; Edwards, S; Mulla, H. Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia. Blood advances. 2023; 7(16):4319-4322.

Piel, FB; Rees, DC; Debaun, MR; Nnodu, O; Ranque, B; Thompson, AA; Ware, RE; Abboud, MR; Abraham, A; Ambrose, EE; Sung, L; Tshilolo, L; Wilkie, DJ; Ohene-Frempong, K. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. The Lancet Haematology. 2023; 10(8):e633-e686.

Ware, J; Mcelhinney, K; Latham, T; Lane, A; Dienger-Stambaugh, K; Hildeman, D; Spearman, P; Ware, RE. Sustained and Boosted Antibody Responses in Breast Milk After Maternal SARS-CoV-2 Vaccination. Breastfeeding Medicine. 2023; 18(8):612-620.

Namazzi, R; Opoka, R; Conroy, AL; Datta, D; Tagoola, A; Bond, C; Goings, MJ; Ryu, M-S; Cusick, SE; Krebs, NF; Jang, JH; Tu, W; Ware, RE; John, CC. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood advances. 2023; 7(13):3023-3031.

Zhou, Z-H; Cortese, MM; Fang, J-L; Wood, R; Hummell, DS; Risma, KA; Norton, AE; Kukuruga, M; Kirshner, S; Rabin, RL; Forshee, R; Broder, KR; Anderson, S; Kozlowski, S. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination. Vaccine. 2023; 41(28):4183-4189.

Dong, M; Ware, RE; Dallmann, A; Vinks, AA. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy. 2023; 43(5):419-429.

Earley, EJ; Kelly, S; Fang, F; Alencar, CS; Rodrigues, DDOW; Soares Cruz, DT; Flanagan, JM; Ware, RE; Zhang, X; Gordeuk, V; Sabino, E; Custer, B; Dinardo, C; Page, GP. Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel loci. British Journal of Haematology. 2023; 201(2):343-352.

Ambrose, EE; Latham, TS; Songoro, P; Charles, M; Lane, AC; Stuber, SE; Makubi, AN; Ware, RE; Smart, LR. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. The Lancet Haematology. 2023; 10(4):e261-e271.

Olupot-Olupot, P; Tomlinson, G; Williams, TN; Tshilolo, L; Santos, B; Smart, LR; Mcelhinney, K; Howard, TA; Aygun, B; Stuber, SE; Lane, A; Latham, TS; Ware, RE. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood. 2023; 141(12):1402-1410.

Torous, DK; Avlasevich, S; Bemis, JC; Howard, T; Ware, RE; Fung, C; Chen, Y; Sahsrabudhe, D; Macgregor, JT; Dertinger, SD. Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients. Environmental and Molecular Mutagenesis. 2023; 64(3):167-175.

Smart, LR; Ambrose, EE; Balyorugulu, G; Songoro, P; Shabani, I; Komba, P; Charles, M; Howard, TA; Mcelhinney, KE; O'hara, SM; Lane, A; Latham, TS; Makubi, AN; Ware, RE. Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. Acta Haematologica. 2023; 146(2):95-105.

Smart, LR; Charles, M; Mcelhinney, KE; Dong, M; Power-Hays, A; Howard, T; Vinks, AA; Ambrose, EE; Ware, RE. Hydroxyurea pharmacokinetics and precision dosing in low-resource settings. Frontiers in Molecular Biosciences. 2023; 10:1130206.

Green, NS; Zapfel, A; Nnodu, OE; Franklin, P; Tubman, VN; Chirande, L; Kiyaga, C; Chunda-Liyoka, C; Awuonda, B; Ohene-Frempong, K; Thompson, AA; Berliner, N; Coetzer, TL; Novelli, EM. The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood advances. 2022; 6(24):6187-6197.

Makani, J; Cavazzana, M; Gupta, K; Nnodu, O; Odame, I; Tshilolo, L; Ware, R; Luzzatto, L. Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need. American Journal of Hematology. 2022; 97(12):1505-1506.

Dong, M; Sadaf, A; Vinks, AA; Ware, RE; Quinn, CT. Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Blood. 2022; 140(Supplement 1):8256-8257.

Dong, M; Good, A; Vinks, AA; Ware, RE; Mcgann, PT. Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT) Blood. 2022; 140(Supplement 1):8168-8169.

Power-Hays, A; Dandoy, CE; Lorts, A; Perentesis, JP; Unaka, N; Ware, RE; Mcgann, PT. US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69(8):e29679.

Quinn, CT; Ware, RE. New therapeutics for children with sickle cell disease: A time for celebration, caution, or both? Pediatric Blood and Cancer. 2022; 69(8):e29805.

R., N; A., C; C., B; M., G; D., D; R., W; R., O; C., J. PI‐08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA. HemaSphere. 2022; 6(Suppl):13-13.

L., S; M., C; A., P; T., H; K., M; E., A; R., W. O‐12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW‐RESOURCE SETTINGS. HemaSphere. 2022; 6(Suppl):7-8.

A., P; G., T; L., T; B., S; T., W; P., O; L., S; P., M; S., S; T., L; R., W. O‐01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB‐SAHARAN AFRICA: THE REACH EXPERIENCE. HemaSphere. 2022; 6(Suppl):1-1.

Nima, MK; Mukherjee, A; Sazed, SA; Hossainey, MRH; Phru, CS; Johora, FT; Safeukui, I; Saha, A; Khan, AA; Marma, ASP; Haque, R; Khan, WA; Alam, MS; Haldar, K. Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. mBio. 2022; 13(1):e0344421.

Quinn, CT; Ware, RE. Reproductive equity: preserve the reserve. Blood. 2022; 139(7):963-965.

Macharia, AW; Mochamah, G; Makale, J; Howard, T; Mturi, N; Olupot-Olupot, P; Färnert, A; Ware, RE; Williams, TN. Case Report: β-thalassemia major on the East African coast. Wellcome Open Research. 2022; 7:188.